View Item 

Show simple item record

The Diabetes Subgroup Baseline Characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial
dc.contributor.authorBakris, Georgeen_US
dc.contributor.authorHester, Allenen_US
dc.contributor.authorWeber, Michaelen_US
dc.contributor.authorDahlof, Bjornen_US
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorVelasquez, Ericen_US
dc.contributor.authorStaikos-Byrne, Lindaen_US
dc.contributor.authorShi, Victoren_US
dc.contributor.authorJamerson, Kenen_US
dc.date.accessioned2010-06-01T20:06:56Z
dc.date.available2010-06-01T20:06:56Z
dc.date.issued2008-09en_US
dc.identifier.citationBakris, George; Hester, Allen; Weber, Michael; Dahlof, Bjorn; Pitt, Bert; Velasquez, Eric; Staikos-Byrne, Linda; Shi, Victor; Jamerson, Ken (2008). "The Diabetes Subgroup Baseline Characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial." Journal of the CardioMetabolic Syndrome 3(4): 229-233. <http://hdl.handle.net/2027.42/73240>en_US
dc.identifier.issn1559-4564en_US
dc.identifier.issn1559-4572en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73240
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19040592&dopt=citationen_US
dc.format.extent241569 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2008 Le Jacqen_US
dc.titleThe Diabetes Subgroup Baseline Characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trialen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherFrom the Hypertensive Diseases Unit, Department of Medicine, University of Chicago School of Medicine, Chicago, ILen_US
dc.contributor.affiliationotherDepartment of Biostatistics, Novartis Pharmaceuticals, East Hanover, NJen_US
dc.contributor.affiliationotherDepartment of Medicine, SUNY Downstate, Brooklyn, NYen_US
dc.contributor.affiliationotherDepartment of Medicine, University of Goteborg, Goteborg, Swedenen_US
dc.contributor.affiliationotherDuke University Medical Center and Duke Clinical Research Institute, Durham, NCen_US
dc.contributor.affiliationotherNovartis, East Hanover, NJen_US
dc.identifier.pmid19040592en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73240/1/j.1559-4572.2008.00023.x.pdf
dc.identifier.doi10.1111/j.1559-4572.2008.00023.xen_US
dc.identifier.sourceJournal of the CardioMetabolic Syndromeen_US
dc.identifier.citedreferenceFox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004; 292 ( 20 ): 2495 – 2499.en_US
dc.identifier.citedreferenceJamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004; 17 ( 9 ): 793 – 801.en_US
dc.identifier.citedreferenceWeber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16 ( 1 ): 13 – 19.en_US
dc.identifier.citedreferenceJulius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363 ( 9426 ): 2022 – 2031.en_US
dc.identifier.citedreferenceDahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366 ( 9489 ): 895 – 906.en_US
dc.identifier.citedreference 6 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288 ( 23 ): 2981 – 2997.en_US
dc.identifier.citedreferenceWeber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004; 363 ( 9426 ): 2049 – 2051.en_US
dc.identifier.citedreference 8 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42 ( 6 ): 1206 – 1252.en_US
dc.identifier.citedreferenceWhelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005; 165 ( 12 ): 1401 – 1409.en_US
dc.identifier.citedreferenceBakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001; 161 ( 22 ): 2661 – 2667.en_US
dc.identifier.citedreferenceMancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003; 41 ( 3 ): 431 – 436.en_US
dc.identifier.citedreferenceJamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16 ( 2 ): 80 – 86.en_US
dc.identifier.citedreferenceBakris GL, Weir MR. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003; 5 ( 3 ): 202 – 209.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1559-4572.2008.00023.x.pdf
Size:
235.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.